Absci reported quarterly losses of 25 cents per share which missed the analyst consensus estimate of 23 cents per share. This ...
The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...
Reports Q4 revenue $665K, consensus $1.77M.”Looking back on 2024, it is inspiring to see the significant progress our AI Integrated Drug ...
Pre-earnings options volume in AbSci Corp is normal with calls leading puts 8:3. Implied volatility suggests the market is anticipating a move near 16.5%, or 51c, after results ar ...
In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment ...
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...
I think it's leveraging AI." Sean McClain, founder and CEO of Absci, and Christian Stegmann, SVP of Drug Creation, sit down with Andrew Galler to discuss Absci's generative AI platform and ...
Absci (NASDAQ:ABSI – Get Free Report) will likely be posting its quarterly earnings results after the market closes on Tuesday, March 18th. Analysts expect Absci to post earnings of ($0.23) per share ...
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025 ...
The company posted revenue of $0.7 million for Q4 2024, falling short of the $1.8 million consensus estimate. Adjusted earnings per share came in at -$0.25, $0.03 worse than analysts expected.
Absci management is scheduled to participate in a fireside chat on Monday, March 3rd at 3:10 p.m. Eastern Time (12:10 p.m. Pacific Time). Interested parties may access a live and archived webcast ...